Reproductive System Neoplasm

In this randomized, phase II trial, 61 patients with primary stage III or IV or recurrent HER2/neu-positive uterine serous carcinoma. Participants were randomly assigned to receive carboplatin-paclita… (full text at CIViC)

PMID 29584549 · Fader et al., 2018 · Open in CIViC

In a randomized phase 2 trial, patients who have uterine serous carcinoma that overexpress erbb2 were allocated carboplatin-paclitaxed with or without trastuzumab. Median progression-free survival was… (full text at CIViC)

PMID 29584549 · Fader et al., 2018 · Open in CIViC

Ovarian epithelial tumours (n=235) were used to create TMAs and IHC results were scored for ERCC1 (n=114 low, n=121 high). For platinum sensitive patients (n=250 in supplementary table, but not all ha… (full text at CIViC)

PMID 30797591 · Mesquita et al., 2019 · Open in CIViC

In uterine tumors resembling ovarian sex cord tumor (UTROSCT; n = 4), RNA sequencing identified recurrent ESR1::NCOA3 (n = 2), ESR1::NCOA2 (n = 1), and GREB1::NCOA2 (n = 1) fusions, involving NCOA2/3 … (full text at CIViC)

PMID 30273195 · Dickson et al., 2019 · Open in CIViC

In a retrospective UTROSCT cohort (n = 17, follow-up n = 13), 3 patients (23.1%) carrying GREB1::NCOA2, ESR1::NCOA3 or ESR1::CITED2 fusions developed pelvic, abdominal or pulmonary recurrence, with re… (full text at CIViC)

PMID 38000680 · Qijun et al., 2024 · Open in CIViC

In a clinical study including 144 patients, nuclear beta-2 expression is significantly correlated with decreased RFS (p < 0.01), decreased MFS (p < 0.01) and PSA failure (p < 0.01). Moreover cytoplasm… (full text at CIViC)

PMID 20501637 · Leung et al., 2010 · Open in CIViC

Immunohistochemical methods were used to evaluate the expression levels of ETV4 in prostate cancer (PCa) tumor samples. Increased expression of ETV4 was associated with greater Gleason score (P = 0.04… (full text at CIViC)

PMID 25544710 · Qi et al., 2015 · Open in CIViC

A patient with prostate cancer with exceptional response to treatment was identified who harbored a somatic hemizygous deletion of the DNA repair gene FANCA and putative partial loss of function of th… (full text at CIViC)

PMID 26181256 · Beltran et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

243 primary PCa, 37 metastatic PCa, and 20 castration-resistant PCa (CRPC) specimens underwent IHC and microarray analysis. Immunohistochemistry (IHC) showed that FGF13 was detectable in the major… (full text at CIViC)

PMID 26891277 · Yu et al., 2016 · Open in CIViC

In a retrospective study, the association between biomarker and prognosis in patients with advanced ovarian cancer were evaluated. High expression FGFR4 or FGF19 were associated with poor overall surv… (full text at CIViC)

PMID 26323668 · Hu et al., 2015 · Open in CIViC

Phase 1 study of pan-FGFR inhibitor JNJ-42756493 in patients with solid tumors. No responses were seen 36 patients without FGFR pathway aberrations. Among 23 patients with FGFR pathway aberrations, 4 … (full text at CIViC)

PMID 26324363 · Tabernero et al., 2015 · Open in CIViC

patients with FGFR2 mutations had a much higher incidence of progression (32/125, 26%) whereas among those with wild type where only (120/848,14%) displayed incidences of progression. The mutated FGFR… (full text at CIViC)

PMID 28314589 · Jeske et al., 2017 · Open in CIViC

Treatment of cell lines harboring FGFR2 mutations with dovitinib 0.5 mmol/L for 72 hours resulted in a significant decrease in cell viability of AN3CA (37.80%) and MFE-296 (53.14%). Conversely, in cel… (full text at CIViC)

PMID 24448819 · Eritja et al., 2014 · Open in CIViC

The endometrial cancer cell lines, AN3CA and MFE296, which carry the N550K FGFR2 mutation, were found to be sensitive to FGFR inhibition with PD174074 (10 to 40x more sensitive than cell lines with wi… (full text at CIViC)

PMID 18757403 · Byron et al., 2008 · Open in CIViC

A study that aims to analyse the biological significance of the FGFR3-TACC3 fusion. They transfected the K508M (also referred to as KD or kinase-dead) FGFR3-TACC3 fusion transcript into cervical epith… (full text at CIViC)

PMID 29358619 · Tamura et al., 2018 · Open in CIViC

In the phase II NCI-MATCH EAY131-K2 trial, a patient with malignant Brenner tumor of the ovary harboring an FGFR3 S249C (p.Ser249Cys) mutation achieved a partial response to erdafitinib, with a 73.9% … (full text at CIViC)

PMID 38603650 · Gong et al., 2024 · Open in CIViC

Phase II study (NCT02465060) from NCI-MATCH Trial (EAY131) Subprotocol W addressed the use of AZD4547 (an FGFR 1-3 inhibitor) in 48 tumor patients carrying FGFR 1-3 variants. Partial responses were ob… (full text at CIViC)

PMID 32463741 · Chae et al., 2020 · Open in CIViC

In a retrospective study, the association between biomarker and prognosis in patients with advanced ovarian cancer were evaluated. High expression FGFR4 or FGF19 were associated with poor overall surv… (full text at CIViC)

PMID 26323668 · Hu et al., 2015 · Open in CIViC

57 from 105 patients in the AGo-OVAR-15 trial were retrospectively genotyped for FNTB polymorphisms. Resistance to lonafarnib-containing treatment was limited to patients with a FNTB rs11623866 (c.-60… (full text at CIViC)

PMID 26033044 · Bachmann et al., 2015 · Open in CIViC

FOXL2 mutations were found in 94% of pathologically confirmed A-GCTs (95/101), in one of eight juvenile granulosa cell tumours (J-GCTs), and in two of 19 SLCTs.

PMID 26033501 · Goulvent et al., 2016 · Open in CIViC

FOXL2 C134W mutation was found in 52 / 56 adult granulosa cell tumors, and is absent in other types of sex-cord stromal tumors, and juvenile granulosa tumors.

PMID 20693978 · Jamieson et al., 2010 · Open in CIViC

GADD45A (1506T>C) association with ovarian cancer was investigated with 258 ovarian cancer patients and 332 age matched healthy women as controls using sequence analysis. A significant difference in g… (full text at CIViC)

PMID 26422378 · Yuan et al., 2015 · Open in CIViC

Prostate Cancer (PCa) cell lines were either cultured alone, co-cultured with osteoblasts expressing GAS6, or cultured in the presence of media with GAS6 to examine their response to therapy with doce… (full text at CIViC)

PMID 27153245 · Lee et al., 2016 · Open in CIViC

This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC)

PMID 39413348 · Weitz et al., 2025 · Open in CIViC

Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC)

PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC

Stable GSTP1 knockdown in ovarian carcinoma A2780 cell lines showed increased sensitivity to platinum-based chemotherapy drugs carboplatin, cisplatinum, carboplatin, and paclitaxel. For each drug, 3 b… (full text at CIViC)

PMID 25010864 · Sawers et al., 2014 · Open in CIViC

G84E (rs138213197) substitution in HOXB13 is associated with an increased risk for prostate cancer. 49 out of 9012 male patients in the Mayo Clinic Biobank were carriers. 31% of patients were diagnose… (full text at CIViC)

PMID 26108461 · Beebe-Dimmer et al., 2015 · Open in CIViC

Meta-analysis of prostate cancer with sixteen case-control studies including 50,048 cases and 123,211 controls. In a random effect model the pooled OR (3.38 (95% CI: 2.45–4.66)) of the studies suppor… (full text at CIViC)

PMID 27626483 · Zhang et al., 2016 · Open in CIViC

Fresh tumor tissue 291 cervical cancer patients was fresh frozen at -70 degrees. DNA from samples was purified and analyzed via PCR for HPV 16, 18, and 6. HPV was found in 247 (85%) of tumors. HPV-16 … (full text at CIViC)

PMID 8827013 · Burger et al., 1996 · Open in CIViC

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resi… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

Phase 2 trial of capivasertib in solid cancer patients with AKT1/2/3 alterations. One patient with metastatic prostate cancer and in-frame AKT2 L78_Q79ins(HANTFVIRCL) that previously progressed on enz… (full text at CIViC)

PMID 35440569 · Shrestha Bhattarai et al., 2022 · Open in CIViC

In prostate cancer cell lines with loss of the Y-linked histone demethylase KDM5D (knockdown in LNCaP and VCaP, or deletion in LNCaP-104R2 and E006AA), ATR signaling was activated, and the selective A… (full text at CIViC)

PMID 29863497 · Komura et al., 2018 · Open in CIViC

Case Report of a 42-year old patient with low-grade endometrial stromal sarcoma. IHC was focally positive for CD117. Imatinib mesylate led to complete metabolic response (PET-CT).

PMID 18607592 · Kalender et al., 2009 · Open in CIViC

Case Report of a 41-year old patient with high-grade stromal endometrial sarcoma and a large abdominal and retroperitoneal mass progressing after chemotherapy. IHC for c-Kit was positive and treatment… (full text at CIViC)

PMID 16487996 · Salvatierra et al., 2006 · Open in CIViC

In prostate cancer (PCa) cell models (PC-3 and DU145; shRNA/siRNA knockdown of KMT2D), loss of enhancer activity markers H3K4me1/H3K27ac reduced FOXO3 protein abundance and DNA binding and suppressed … (full text at CIViC)

PMID 31232159 · Lv et al., 2019 · Open in CIViC

In this study, KRAS gain (KRAS/CEP12q ratio >1 and <2) or amplification (ratio >2) was detected in 3% (13 of 414) of the primary endometrial carcinomas investigated. Presence of KRAS gain or amplifica… (full text at CIViC)

PMID 23099803 · Birkeland et al., 2012 · Open in CIViC

In an in vitro study, a MCAS cell line expressing KRAS G12D mutation was associated with reduced sensitivity to cetuximab treatment as compared to RMUG-L and OMC-1 cells expressing wild-type KRAS. Res… (full text at CIViC)

PMID 22246397 · Sato et al., 2012 · Open in CIViC

40 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRA… (full text at CIViC)

PMID 27502722 · Pietrantonio et al., 2016 · Open in CIViC

In an open-label, multicenter phase II study of recurrent low-grade serous ovarian cancer (ENGOT-OV60/GOG-3052/RAMP 201; NCT04625270), patients were stratified by KRAS mutation status and treated with… (full text at CIViC)

PMID 40644648 · Banerjee et al., 2025 · Open in CIViC

A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC)

PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC

The functional variant rs61764370 in the KRAS gene 3' UTR (KRAS-variant) was found to be correlated with platinum-based chemotherapy resistance in patients with Epithelial Ovarian Cancer (EOC). 291 EO… (full text at CIViC)

PMID 22139083 · Ratner et al., 2012 · Open in CIViC